Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EPS (Weighted Average and Diluted) (2018 - 2025)

Ocular Therapeutix (OCUL) has 8 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.27 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 3.57% year-over-year to -$0.27; the TTM value through Dec 2025 reached -$1.42, down 13.6%, while the annual FY2025 figure was -$1.42, 16.39% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.27 in Q4 2025 per OCUL's latest filing, up from -$0.38 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.22 in Q1 2022 and bottomed at -$0.49 in Q1 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.29, with a median of -$0.26 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 82.17% in 2021, then tumbled 77.27% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.23 in 2021, then fell by 4.35% to -$0.24 in 2022, then dropped by 4.17% to -$0.25 in 2023, then decreased by 12.0% to -$0.28 in 2024, then increased by 3.57% to -$0.27 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.27 in Q4 2025, -$0.38 in Q3 2025, and -$0.39 in Q2 2025.